Research Article

Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Tear Production in a Mouse Model of Sjögren’s Syndrome

Hema S. Aluri,1 Mahta Samizadeh,1 Maria C. Edman,2 Dillon R. Hawley,1 Helene L. Armaos,1 Srikanth R. Janga,2 Zhen Meng,3 Victor G. Sendra,4 Pedram Hamrah,4,5 Claire L. Kublin,1 Sarah F. Hamm-Alvarez,2,3 and Driss Zoukhri1,4

1Department of Comprehensive Care, Tufts University School of Dental Medicine, Boston, MA, USA
2Department of Ophthalmology, USC Roski Eye Institute, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA
3University of Southern California School of Pharmacy, Los Angeles, CA, USA
4Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA
5Center for Translational Ocular Immunology, Department of Ophthalmology, Tufts University School of Medicine, Boston, MA, USA

Correspondence should be addressed to Driss Zoukhri; driss.zoukhri@tufts.edu

Received 14 September 2016; Revised 2 December 2016; Accepted 21 December 2016; Published 2 March 2017

Academic Editor: Dominik Wolf

Copyright © 2017 Hema S. Aluri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The purpose of the present study was to test the potential of mouse bone marrow-derived mesenchymal stem cells (BD-MSCs) in improving tear production in a mouse model of Sjögren’s syndrome dry eye and to investigate the underlying mechanisms involved. NOD mice (n = 20) were randomized to receive i.p. injection of sterile phosphate buffered saline (PBS, control) or murine BD-MSCs (1 × 10^6 cells). Tears production was measured at baseline and once a week after treatment using phenol red impregnated threads. Cathepsin S activity in the tears was measured at the end of treatment. After 4 weeks, animals were sacrificed and the lacrimal glands were excised and processed for histopathology, immunohistochemistry, and RNA analysis. Following BD-MSC injection, tears production increased over time when compared to both baseline and PBS injected mice. Although the number of lymphocytic foci in the lacrimal glands of treated animals did not change, the size of the foci decreased by 40.5% when compared to control animals. The mRNA level of the water channel aquaporin 5 was significantly increased following delivery of BD-MSCs. We conclude that treatment with BD-MSCs increases tear production in the NOD mouse model of Sjögren’s syndrome. This is likely due to decreased inflammation and increased expression of aquaporin 5.

1. Introduction

Sjögren’s syndrome is an autoimmune disease which chronically affects the lacrimal and salivary glands, leading to dry eye disease and dry mouth (xerostomia) [1, 2]. Dry eye disease caused by Sjögren’s syndrome is associated with corneal injury and recurrent eye infections that may lead to impairment of vision. Furthermore, symptoms of dry eye result in loss of quality of life comparable to that caused by angina. Although the etiology of Sjögren’s syndrome is not yet clear, B lymphocyte hyperreactivity, autoantibody production, and T cell lymphocytic infiltration to exocrine glands and other organs have been observed in patients diagnosed with Sjögren’s syndrome [3, 4].

In recent years, there has been an emerging interest in stem cells therapy for autoimmune diseases. One group of stem cells that were originally isolated from human bone marrow, but are found in many other adult tissues, are mesenchymal stem cells (MSCs), also termed multipotent stromal cells. MSCs are nonhematopoietic, multipotent progenitor cells that can differentiate in vitro and in vivo to mesenchymal lineages. In addition, MSCs have immunoregulatory...
capabilities that affect both adaptive and innate immunity. MSCs have been reported to secrete interleukin 6 (IL-6) and macrophage-colony stimulating factor to suppress T and B lymphocyte proliferation [5–7] along with the release of anti-inflammatory and antiapoptotic molecules that protect damaged tissues [8]. Addition of MSCs to in vitro activated T cell cultures resulted in decreased production of proinflammatory cytokines and increased levels of anti-inflammatory cytokines [6, 9–11]. Even though in vitro and in vivo studies support the therapeutic efficacy of MSCs, the mechanisms by which MSCs exert immunomodulatory and tissue repair processes are still not completely understood.

Xu et al. showed that treatment with BD-MSCs, or umbilical cord derived MSCs, suppressed autoimmune and restored salivary gland secretory function both in a mouse model and in Sjögren’s syndrome patients [12]. In another study, Khalili et al. found that CD45⁻/TER119⁻ BD-MSCs injected into female NOD mice restored normal salivary secretion [13]. From several studies involving MSC therapy in autoimmune diseases, it is apparent that MSCs are not replacing the tissue by differentiating into specific tissue lineage but they are exerting a complex pattern of immunomodulatory, anti-inflammatory, and regenerative signaling effects that help in attenuating the disease condition [6]. At the time of writing this article, there are 311 registered clinical trials in progress using MSCs (http://www.clinicaltrials.gov/), including one study for Sjögren’s syndrome.

Our lab has performed extensive research on the mechanisms involved in dry eye and dry mouth in human and animal models of Sjögren’s syndrome [14–19]. We reported that stem/progenitor cells were present in the murine lacrimal gland and the number of these cells increased during the repair phase after experimentally induced inflammation [16]. We also have found evidence that MSCs in murine lacrimal glands can be activated during tissue repair [20]. Since BD-MSCs display definite immunomodulation and immunosuppressive properties as well as regenerative potential, there is a strong rationale for using MSC-based therapy for treatment of Sjögren’s syndrome dry eye. Thus, the purpose of the present study was to test the hypothesis that a single injection of BD-MSCs will restore normal tear production in a mouse model of Sjögren’s syndrome.

2. Materials and Methods

2.1. Materials. Iscove’s Modified Dulbecco’s Medium (IMDM), gentamicin, penicillin, streptomycin, heat-inactivated fetal bovine serum (FBS), L-glutamine, trypsin-EDTA, and trypsin replacement (TrypLE Express) were obtained from Invitrogen (Carlsbad, CA). Costar culture treated plates were from Corning Life Sciences (Lowell, MA). The miRNeasy isolation kit and OneStep RT-PCR Kit were purchased from Qiagen (Valencia, CA). Primers were designed using NCBI/Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Phenol red impregnated cotton threads were obtained from Zone-Quick, Lacrimedics (Eastsound, WA). Paraplast™ plus tissue embedding medium, eosin, and modified hematoxylin were obtained from Fisher Healthcare (Houston, TX). For the immunohistochemistry experiments, the antigen retrieval solution and DAPI were from Vector Laboratories (Burlingame, CA) whereas the donkey serum was purchased from Jackson ImmunoResearch (Westgrove, PA). Bovine serum albumin (BSA, fraction V) was purchased from Fisher Scientific (Waltham, MA). The following primary antibodies were used: purified rat anti-mouse Foxp3 (1:100; clone FJK-16s, ebioscience, San Diego, CA) and rabbit polyclonal to Foxp3 (1:100, Abcam, Cambridge, MA). Secondary antibodies were as follows: Alexa Fluor® 488 donkey anti-rat IgG and Alexa Fluor® 488 donkey anti-rabbit IgG (1:100; Invitrogen, Eugene, OR). For CTSS assay, the Cathepsin S Activity Fluorometric Assay Kit (BioVision, Milpitas, CA) was used.

2.2. Animals and Treatments. The studies described herein were performed at two sites, Tufts University and the University of Southern California. Male NOR/LtJ (referred to as NOD) mice were purchased or bred in house from breeding pairs purchased from the Jackson Laboratories (Bar Harbor, ME). All experiments were performed in accordance with the Association of Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Tufts Medical Center and University of Southern California Animal Care and Use Committees.

BD-MSCs isolated from C57BL/6-Tg (UBC-GFP) mice (a generous gift from Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White) were injected intraperitoneally into NOD mice. The protocols for isolation and propagation of mouse BD-MSCs were published by Peister et al. [21]. The published culture protocol was used for propagation of the donated BD-MSCs. Thirteen-week-old male NOD mice (n = 10 per group) were randomized to receive PBS (control) or BD-MSCs (1 × 10⁶ cells/mouse in 0.2 mL PBS) intraperitoneally. Following 4 weeks of treatment, the animals were sacrificed and the exorbital lacrimal glands were removed and divided into two equal pieces. One piece of the lacrimal gland was fixed, embedded in paraffin, and used for histopathology and immunohistochemistry studies. From the second piece of the lacrimal gland, total RNA was extracted and used for PCR analyses.

2.3. Tear Measurement and Cathepsin S Assay. Mice were lightly anesthetized using isoflurane and tear production was measured using phenol red impregnated cotton threads, as previously described [22]. The threads were held with jeweler forceps and applied in both eyes at the lateral canthus of the ocular surface for 10 sec. Upon contact with the tears, the color of the thread changes from yellow to red. The length of the thread that changed color was then measured, in millimeters, using a dissecting microscope. Following 4 weeks of treatment, stimulated tears were collected and used for cathepsin S (CTSS) assay. Briefly, mice were anesthetized with ketamine and xylazine and then the eye was washed with a drop of eye irrigating solution (Eyestream, Alcon).
small incision was made between the eye and ear to expose the exorbital lacrimal gland followed by the application of 3 μL of a 50 μM carbamylcholine solution (an analog of the parasympathetic agonist acetylcholine) topically to the gland, 3 times in 5-minute intervals. Tear fluid was then collected with a 2 μL glass capillary at the lateral canthus of the eye for a total of 15 minutes. Tear fluid was analyzed for CTSS activity using a commercially available kit (BioVision) according to the manufacturer's instructions. Briefly, 100 μL of diluted tear sample with CS reaction buffer and 2 μL of the CTSS substrate Z-VVR-AFC (the tripeptide Val-Val-Arg conjugated to 7-amino-4-trifluoromethyl coumarin [AFC]) were loaded into a 96-well clear plate in the presence or absence of the supplied CTSS inhibitor, followed by incubation at 37 °C for 1 hour. The quantity of free AFC obtained by the reaction of CTSS with substrate was measured using a SpectraMax Gemini EM spectrofluorometer (Molecular Devices) with excitation at 400 nm and emission at 505 nm. CTSS-specific activity was calculated as:

\[
\frac{\sum \text{area of individual focus in a given section}}{\text{total section area}} \times 100 \quad (1)
\]

The slides were masked and two individuals performed the histologic analysis as a blindfolded experiment.

2.4. Histopathology and Measurement of Lymphocytic Foci Number/Size. Lacrimal glands were fixed in 4% formaldehyde in phosphate buffered saline (PBS, containing NaCl 145 mM, Na₂HPO₄ 7.3 mM, and NaH₂PO₄ 2.7 mM at pH 7.2) and embedded in paraffin. Paraffin sections of the lacrimal gland (6 μm) were deparaffinized followed by rehydration in graded alcohol solutions prior to staining. For histopathology experiments, slides were processed for hematoxylin and eosin staining and lymphocytic foci were counted. Images were obtained using a Nikon UFXII microscope coupled to a SPOT™ digital camera. A lymphocytic focus was defined as a focus containing 50 or more mononuclear cells. The size and number of lymphocytic foci, in addition to the total section area, were determined in 5–8 nonconsecutive sections per gland. The percentage of the area occupied by a focus was calculated as:

\[
\frac{\text{area of individual focus in a given section}}{\text{total section area}} \times 100 \quad (1)
\]

The slides were masked and two individuals performed the histologic analysis as a blindfolded experiment.

2.5. Immunofluorescence Staining. Lacrimal glands from tissue embedded paraffin were used to prepare 6 μm sections. After heat-induced antigen retrieval, the sections were permeabilized with 0.1% Triton X-100 (in PBS) for 10 min. Next, F₃, antigen-binding fragments were blocked using 10% (w/v) normal donkey serum diluted in 1% (w/v) bovine serum albumin (BSA) in PBS, for 1 h at room temperature. Sections were then incubated with purified rat anti-forkhead box P3 (Foxp3) or rabbit anti-Foxp3 primary antibodies overnight at 4 °C or for 1 hour at 37 °C, respectively. Subsequently, sections were incubated with the appropriate secondary antibody, AlexaFluor® 488 donkey anti-rat IgG for 1 hour at room temperature or AlexaFluor 488 donkey anti-rabbit IgG for 1 hour at 37°C. For negative controls, incubation without the primary antibody was performed. Finally, sections were mounted in Vectashield mounting medium containing DAPI or ProLong Gold Antifade Mounting Media. Sections were examined with a fluorescence microscope to identify and count the number of Foxp3⁺ cells/focus.

2.6. RNA Extraction and RT-PCR/qPCR. Total RNA was extracted using the miRNA isolation kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. Briefly, lacrimal glands were homogenized in QIAzol lysis reagent and incubated at room temperature for 5 min. To the homogenate, chloroform was added and centrifuged at 12,000 × g at 4°C. Next, the upper aqueous layer was collected and mixed with 1.5 volumes of 100% ethanol which was run through an RNase MinElute spin column at 8000 × g for 15 seconds. Buffers RWT, RPE, and 80% ethanol were run through the column, in sequence, using centrifugation at 8000 × g for 15 seconds each time. Lastly, 20 μL of RNase-free water was added to the spin column and the RNA was collected. RNA purity and quantity was analyzed using a NanoDrop 1000. The samples were then stored at −20°C until being used for downstream applications.

For qPCR, total RNA was converted to cDNA using a reverse transcription kit (Thermo Scientific, Grand Island, NY) following manufacturer's protocol. qPCR was then performed using specific TaqMan primers and probes against CTSS, major histocompatibility complex II (MHC-II), matrix metalloproteinase 9 (MMP9), Rab3D, Rab27A, Rab27B, interleukin 12a (IL-12a), interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), aquaporin 5 (Aqp5), M3R, and GAPDH as a housekeeping gene (Table 2). An ABI Open Array Real-Time PCR System (Life Technologies, Grand Island, NY) was used to read the plate and the data obtained was analyzed using the ΔΔCT method.

2.7. Statistical Analysis. All data are expressed as means ± standard error of the mean (SEM) and data consisting of two groups was analyzed by two-tailed Student's t-test using GraphPad Prism Version 5.0 software (GraphPad Software, San Diego, CA).
Table 1: List of primers used in reverse transcriptase polymerase chain reaction.

| Gene name | Primers | Amplicon size (bp) |
|-----------|---------|-------------------|
| Foxp3     | F: GGC AAT AGT TCC TTC CCA GAG T<br>R: ATG GCC CAT CGG ATA AGG GTG<br>F: TGC CGC ACT TCC ACT CTC G<br>R: TCA GCC GTG CAA CAA TCT GA<br>F: TGT TGC CAT GGA ACC GAT CA<br>R: TGG TGG GCA GGA AGA TCC TA | 101 254 123 |
| CXCL12    | F: TGCCGCACTTTCACTCTCG<br>R: TCAGCCGTGCAACAATCTGA | 236 |
| CXCR4     | F: TGTTG GCCATGGGAACCGATCA<br>R: TGGTGGGCAGGAAGATCCTA | 123 |
| TSG-6     | F: AAT CCG GCT CAA CAG GAG TG<br>R: CAT AGT CAG CCA AGC AGC CT<br>F: ACC ACA GTG CAT GCC ATC AC<br>R: TCC ACC CGT TTG CTA | 236 |
| GAPDH     | F: A CCA CAGTCCA TGCCA TCA C<br>R: TCCACCACCCTGTTGCTGTA | 452 |

Table 2: List of primers used in quantitative polymerase chain reaction.

| Gene name | Cat # (ThermoFisher Scientific) | Amplicon size (bp) |
|-----------|---------------------------------|-------------------|
| CTSS      | Mm01255859_m1                   | 75                |
| MHC-II    | Mm00439216_m1                   | 112               |
| MMP9      | Mm00442991_m1                   | 76                |
| Rab3D     | Mm01151273_mH                   | 94                |
| Rab27A    | Mm00469997_m1                   | 61                |
| Rab27B    | Mm00472653_m1                   | 66                |
| IL-12a    | Mm00434165_m1                   | 68                |
| IFN-gamma | Mm01168134_m1                   | 100               |
| TNF-alpha | Mm00443258_m1                   | 81                |
| Aq5       | Mm00437578_m1                   | 60                |
| M3R       | Mm00446300_sl                   | 64                |
| GAPDH     | Mm99999915_g1                   | 109               |

Inc., La Jolla, CA). Values of $p < 0.05$ were considered statistically significant.

3. Results

3.1. Aqueous Tear Production Increased in BD-MSC Treated NOD Mice. Analysis of tear production (Figure 1) every week posttreatment showed a significant increase in tear volume from the BD-MSC treated group compared to PBS treated group (control). A mean difference between MSC injected and PBS injected of 0.94, 1.58, 2.44, and 1.88 mm/10 s was observed at 1, 2, 3, and 4 weeks after injection, respectively. At each of these measurements, tear volume in MSC injected groups was also significantly increased compared to baseline, with mean differences of 1.17, 1.56, 1.94, and 0.90 mm/10 s, respectively (Figure 1). In contrast, mice treated with PBS showed a downward trend in tear volume over the total course of measurements (Figure 1) which became significant 4 weeks after injection with a mean difference in tear production of $0.98$ mm/10 s.

These data suggest that a single injection of BD-MSCs leads to a sustained improvement in aqueous tears production in NOD mice, a Sjögren’s syndrome animal model of lacrimal gland deficiency.

![Figure 1](image-url)
3.2. BD-MSC Treatment Did Not Alter CTSS Activity in Tears of NOD Mice. The activity of the lysosomal enzyme CTSS is elevated in tears and lacrimal glands of male NOD mice with established dacryoadenitis compared to healthy BALB/c mice [23]. CTSS activity was also found to be increased in tears of Sjögren’s syndrome patients when compared to patients with other autoimmune diseases, nonautoimmune dry eye, and healthy controls [24]. We measured CTSS activity in tears collected from MSC treated animals and those from PBS treated ones. As shown in Figure 2, there was a modest (13.5%), but not statistically significant, decrease in CTSS activity in tears from NOD mice treated with MSCs compared to the PBS treated group.

These data suggest that treatment with BD-MSCs did not significantly affect the activity of CTSS in lacrimal gland tear fluid of NOD mice.

3.3. Lymphocytic Foci Size Was Reduced in BD-MSC Injected Group. To examine whether BD-MSC treatment might ameliorate lymphocyte accumulation in the lacrimal glands of NOD mice, sections were stained with hematoxylin and eosin and evaluated quantitatively to measure the number and size of the lymphocytic foci (as described in Materials and Methods). As shown in Figure 3(a), there was no difference in the average number of lymphocytic foci in sections from BD-MSC treated (5.77 ± 0.95 foci/section) compared to control PBS treated (5.32 ± 0.56 foci/section) mice. In contrast, there was a statistically significant 40.5% decrease in the percentage of the area infiltrated by lymphocytes in the lacrimal glands of animals treated with BD-MSCs (10.57 ± 1.32% infiltrated) when compared to the PBS treated group (17.76 ± 2.63% infiltrated) (Figure 3(b)).
These data indicate that the size of lymphocytic foci decreased in the lacrimal glands of NOD mice treated with BD-MSCs.

3.4. The Number of Foxp3+ Lymphocytes Was Unchanged in BD-MSC Treated Animals. Foxp3 is specifically expressed in CD4+/CD25+ regulatory T cells (Tregs) which are critical cells in active suppression of autoimmune responses [13, 25]. The number of Foxp3+ Tregs was measured in lymphocytic foci in lacrimal gland sections from BD-MSC treated and PBS treated NOD mice. As shown in Figure 4 there was a modest, but not statistically significant, 21% increase in the number of Foxp3+ positive cells in the lymphocytic foci of mice treated with BD-MSCs when compared to those treated with PBS.

These data suggest that treatment with MSCs did not significantly increase the number of regulatory T cells in the lacrimal glands of NOD mice.

3.5. Aquaporin 5 Gene Expression Was Increased in BD-MSCs Treated NOD Mice. Next, we conducted reverse transcriptase PCR experiments to investigate changes in gene expression of Foxp3, CXCL12, CXCR4, and TSG-6, since these genes are naturally involved in modulation of inflammation [12, 26–28]. In addition, expression of several genes known to be dysregulated in Sjögren’s syndrome: CTSS, MHC-II, MMP9, Rab proteins (Rab3D, Rab27A, and Rab27B), IL12α, IFN-γ, TNF-α, and aquaporin 5 (Aq5), and the cholinergic muscarinic M3 receptor (M3R) were quantitatively measured using qPCR. As shown in Figure 5, we did not observe any differences in the expression of genes that are normally involved in modulation of inflammation, genes of proteins (Rab) involved in vesicular trafficking, or of proinflammatory genes. However, and as shown in Figure 5(b), there was a statistically significant increase in the gene expression of Aq5 (5.42 ± 1.06 versus 1.55 ± 0.64, p = 0.013) in the lacrimal glands from BD-MSC treated animals versus those from PBS treated animals. We performed immunostaining using anti-aquaporin 5 and Rab3D antibodies but could not detect a reliably significant increase in staining (data not shown).

These data suggest that increased gene expression of the water channel aquaporin 5 might be responsible for the increased tear production obtained following BD-MSC treatment.
Figure 5: Gene expression of pro- and anti-inflammatory modulators in BD-MSC treated and nontreated NOD mice. Following 4 weeks of treatment total RNA was extracted from the lacrimal glands and used for (a) reverse transcriptase polymerase chain reaction of CXCR4, CXCL12, Foxp3, and TSG6 genes or (b) quantitative polymerase chain reaction of cathepsin S, MHC-II, MMP9, Rab3D, Rab27A, Rab27B, IL-12α, IFN-γ, TNF-α, aquaporin 5, and M3R genes. Data are presented as means ± SEM (RT-PCR, n = 10 for each group; qPCR, n = 7 for each group). * denotes statistically significant difference compared to control.

4. Discussion

Sjögren’s syndrome is a chronic autoimmune disorder of the exocrine glands characterized by inflammation and lymphocytic infiltrates of the affected glands [29]. MSCs from different sources have been successfully used to alleviate experimental and clinical Sjögren’s syndrome symptoms [12, 13, 30, 31]. Notably, several studies reported therapeutic benefits of infused MSCs even though long-term engraftment of these cells could not be detected [32, 33]. MSCs derived from the bone marrow mainly act through the production of soluble trophic factors [32–34] and are involved in tissue repair due to their immunosuppressive and immunomodulatory functions [6, 9, 10].

In a recent study, it has been demonstrated that, following intravenous injection of human MSCs during corneal transplantation, immune rejection was decreased and allograft survival was prolonged [35]. Most of the intravenous infused MSCs were entrapped in the lungs and very few MSCs were found in the corneas after 28 days [35]. Indeed, several studies have reported that only 0.001–0.1% of systemically administered MSCs home to and engraft in sites of inflammation [35–37]. In our study we were unable to identify GFP labeled MSCs in the LG following 4 weeks of treatment. However, it is possible that MSCs did home to the LG in the short term but did not engraft into the tissue. Another study reported that topical MSC therapy in experimental dry eye syndrome improved tear volume and tear film stability [38]. In addition, labeled MSCs were observed in the meibomian glands and conjunctival epithelium along with increase in the number of secretory granules and number of goblet cells [38].

A different study using BD-MSCs in Sjögren’s syndrome-like female NOD mice and human patients showed that the salivary gland secretory function was restored in both mouse models and Sjögren’s syndrome patients [12]. In this study, we showed that mouse BD-MSCs significantly improved tears production, reduced the magnitude of lymphocytic infiltration in the NOD mouse model of Sjögren’s syndrome, and increased the expression of the water channel aquaporin 5.

Tregs are key mediators of peripheral immunological tolerance and their absence results in excessive multisystem autoimmunity in mice and human [39, 40]. Foxp3 is a transcription factor that is specifically expressed on Tregs and is a master control gene for the development and function of CD4+CD25+ Tregs [41]. Interestingly, it has been shown that, infusion of MSCs decreased proinflammatory T cell responses and increased anti-inflammatory T cell responses [12]. IL-10 and TGF-β are anti-inflammatory cytokines secreted by Tregs and they may play a role in mediating MSC responses and accelerating lacrimal gland repair [35, 42, 43]. However, in our study, the number of Foxp3+ Tregs that were found in the inflammatory lesions was not statistically significantly increased in BD-MSC treated lacrimal glands compared to PBS treated groups. These observations suggest that improving lacrimal gland function through BD-MSC treatment in our study does not involve modulation of the inflammatory responses. However, our pathological analyses showed that although the number of lymphocytic foci did not decrease, the size of these foci...
was significantly decreased following injection of BD-MSCs, which could be an indication of attenuated inflammation.

SDF-1/CXCR4 axis is essential in directing BD-MSCs to migrate toward inflammatory sites to control autoimmunity [12, 44]. SDF-1 (CXCL12) ligand and its receptor, CXCR4, are produced during chronic inflammation and play important roles in formation and maintenance of tertiary lymphoid tissues [45]. Interestingly, infused MSCs migrate toward the inflamed area in a SDF-1 dependent manner and blockade of CXCR4 in BD-MSCs with specific antibody could revoke the immunoregulatory activity and consequently the therapeutic effects of normal BD-MSCs [12]. In our study, we could not detect significant changes in the gene expression levels of SDF-1 or CXCR4 following BD-MSC treatment. Similarly, we did not detect any significant changes in the expression of several proinflammatory genes (MHC-II, TNF-α, IL-12a, and MMP9).

Lacrimal gland protein secretion (exocytosis) is regulated in part by a family of Rab proteins which belong to the Ras superfamily of low-molecular-weight GTPases. Of these, Rab3D, Rab27a, and Rab27b have been shown to mediate regulated exocytosis in the lacrimal gland [46–48]. In addition, lacrimal gland fluid secretion is mediated, in part, by the water channel, aquaporin 5 [49]. The expression/localization of Rab proteins and aquaporin 5 has been shown to be altered in Sjögren’s syndrome [50–52]. Our data showing increased expression of Rab3D, Rab27A (although not statistically significant, \( p = 0.053 \) and 0.062, resp.), and aquaporin 5 (\( p = 0.013 \)) following injection of BD-MSCs might explain the effect of this treatment on improving lacrimal gland secretion.

In conclusion, our findings show that a single injection of BD-MSCs improved the secretory function of the lacrimal gland in Sjögren’s syndrome-like diseased mice. This improved production of tears was most likely due to decreased inflammation (size of lymphocytic foci) and increased expression of the water channel aquaporin 5. Additional experiments are needed to further characterize the downstream targets involved in the improved lacrimal gland function in response to MSC delivery.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contributions

Hema S. Aluri and Mahta Samizadeh contributed equally to this work and are listed in alphabetical order.

Acknowledgments

The studies were supported by NIH Grants ROI EY12383 (Driss Zoukhihi and Sarah F. Hammi-Alvarez), R01-EY022695 (Pedram Hamrah), and R21-EY025393 (Pedram Hamrah). Some of the materials employed in this work were provided by the Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White through a grant from ORIP of the NIH, Grant no. P40OD011050.

References

[1] C. Baldini, R. Talarico, A. G. Tzioufas, and S. Bombardieri, “Classification criteria for Sjögren’s syndrome: a critical review,” Journal of Autoimmunity, vol. 39, no. 1-2, pp. 9–14, 2012.
[2] C. P. Mavragani, A. Nezos, and H. M. Moutsopoulos, “New advances in the classification, pathogenesis and treatment of Sjögren’s syndrome,” Current Opinion in Rheumatology, vol. 25, no. 5, pp. 623–629, 2013.
[3] K. Bayetto and R. M. Logan, “Sjögren’s syndrome: a review of aetiology, pathogenesis, diagnosis and management,” Australian Dental Journal, vol. 55, pp. 39–47, 2010.
[4] Y. Peri, N. Agmon-Levin, E. Theodor, and Y. Shoenfeld, “Sjögren’s syndrome, the old and the new,” Best Practice & Research: Clinical Rheumatology, vol. 26, no. 1, pp. 105–117, 2012.
[5] A. Bartholomew, C. Sturgeon, M. Siatskas et al., “Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo,” Experimental Hematology, vol. 30, no. 1, pp. 42–48, 2002.
[6] E. Ben-Ami, S. Berrih-Aknin, and A. Miller, “Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases,” Autoimmunity Reviews, vol. 10, no. 7, pp. 410–415, 2011.
[7] S. Glennie, I. Soeiro, P. J. Dyson, E. W.-F. Lam, and F. Dazzi, “Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells,” Blood, vol. 105, no. 7, pp. 2821–2827, 2005.
[8] K. Le Blanc and O. Ringdén, “Immunomodulation by mesenchymal stem cells and clinical experience,” Journal of Internal Medicine, vol. 262, no. 5, pp. 509–525, 2007.
[9] F. Benvenuto, S. Ferrari, E. Gerdoni et al., “Human mesenchymal stem cells promote survival of T cells in a quiescent state,” Stem Cells, vol. 25, no. 7, pp. 1753–1760, 2007.
[10] Q.-F. Kong, B. Sun, S.-S. Bai et al., “Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-β,” Journal of Neuroimmunology, vol. 207, no. 1-2, pp. 83–91, 2009.
[11] C. Prevosto, M. Zancolli, P. Canevali, M. R. Zocchi, and A. Poggi, “Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction,” Haematologica, vol. 92, no. 7, pp. 881–888, 2007.
[12] J. Xu, D. Wang, D. Liu et al., “Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome,” Blood, vol. 120, no. 15, pp. 3142–3151, 2012.
[13] S. Khalili, Y. Liu, M. Kornet et al., “Mesenchymal stromal cells improve salivary function and reduce lymphocytic infiltrates in mice with Sjögren’s-like disease,” PLoS ONE, vol. 7, no. 6, Article ID e38615, 2012.
[14] S. You, O. Avidan, A. Tariq et al., “Role of epithelial-mesenchymal transition in repair of the lacrimal gland after experimentally induced injury,” Investigative Ophthalmology and Visual Science, vol. 53, no. 1, pp. 126–135, 2012.
[15] D. Zoukhihi, “Effect of inflammation on lacrimal gland function,” Experimental Eye Research, vol. 82, no. 5, pp. 885–898, 2006.
[16] D. Zoukhri, A. Fix, J. Alroy, and C. L. Kublin, “Mechanisms of murine lacrimal gland repair after experimentally induced inflammation,” Investigative Ophthalmology and Visual Science, vol. 49, no. 10, pp. 4399–4406, 2008.

[17] D. Zoukhri, R. R. Hodges, D. Byon, and C. L. Kublin, “Role of proinflammatory cytokines in the impaired lacrimation associated with autoimmune xerophthalmia,” Investigative Ophthalmology & Visual Science, vol. 43, no. 5, pp. 1429–1436, 2002.

[18] D. Zoukhri and C. L. Kublin, “Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren’s syndrome,” Investigative Ophthalmology and Visual Science, vol. 42, no. 5, pp. 925–932, 2001.

[19] D. Zoukhri, I. Rawe, M. Singh et al., “Discovery of putative salivary biomarkers for Sjögren’s syndrome using high resolution mass spectrometry and bioinformatics,” Journal of Oral Science, vol. 54, no. 1, pp. 61–70, 2012.

[20] S. You, C. L. Kublin, O. Avidan, D. Miyasaki, and D. Zoukhri, “Isolation and propagation of mesenchymal stem cells from the lacrimal gland,” Investigative Ophthalmology and Visual Science, vol. 52, no. 5, pp. 2087–2094, 2011.

[21] A. Peister, J. A. Mellad, B. L. Larson, B. M. Hall, L. F. Gibson, and D. J. Prockop, “Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential,” Blood, vol. 103, no. 5, pp. 1662–1668, 2004.

[22] D. Zoukhri, E. Macari, and C. L. Kublin, “A single injection of interleukin-1 induces reversible aqueous-tear deficiency, lacrimal gland inflammation, and acinar and ductal cell proliferation,” Experimental Eye Research, vol. 84, no. 5, pp. 894–904, 2007.

[23] X. Li, K. Wu, M. Edman et al., “Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse,” Investigative Ophthalmology and Visual Science, vol. 51, no. 10, pp. 5019–5029, 2010.

[24] S. F. Hamm-Alvarez, S. R. Janga, M. C. Edman et al., “Tear cathepsin S as a candidate biomarker for sjögren’s syndrome,” Arthritis and Rheumatology, vol. 66, no. 7, pp. 1872–1881, 2014.

[25] J. D. Fontenot, M. A. Gavin, and A. Y. Rudensky, “Foxp3 programs the development and function of CD4+CD25+ regulatory T cells,” Nature Immunology, vol. 4, no. 4, pp. 330–336, 2003.

[26] M. I. Christodoulou, E. K. Kapsogeorgou, N. M. Moutsopoulos, and H. M. Moutsopoulos, “Foxp3+ T-regulatory cells in Sjögren’s syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors,” American Journal of Pathology, vol. 173, no. 5, pp. 1389–1396, 2008.

[27] R. H. Lee, J. M. Yu, A. M. Foskett et al., “TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 47, pp. 16766–16771, 2014.

[28] D. J. Prockop, “Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation,” STEM CELLS, vol. 31, no. 10, pp. 2042–2046, 2013.

[29] R. I. Fox, “Sjögren’s syndrome,” The Lancet, vol. 366, no. 9482, pp. 321–331, 2005.

[30] A. Alunno, P. Montanucci, O. Bistoni et al., “In vitro immunomodulatory effects of microencapsulated umbilical cord Wharton jelly-derived mesenchymal stem cells in primary Sjögren’s syndrome,” Rheumatology (United Kingdom), vol. 54, no. 1, Article ID keu292, pp. 163–168, 2014.

[31] D. L. Faustman and M. Davis, “Stem cells in the spleen: therapeutic potential for Sjögren’s syndrome, type 1 diabetes, and other disorders,” The International Journal of Biochemistry & Cell Biology, vol. 42, no. 10, pp. 1576–1579, 2010.

[32] R. H. Lee, A. A. Pulim, M. J. Seo et al., “Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6,” Stem Cell, vol. 5, no. 1, pp. 54–63, 2009.

[33] Y. Iso, J. L. Spees, C. Serrano et al., “Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment,” Biochemical and Biophysical Research Communications, vol. 354, no. 3, pp. 700–706, 2007.

[34] G. W. Roddy, J. Y. Oh, R. H. Lee et al., “Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-α stimulated gene/protein 6,” Stem Cells, vol. 29, no. 10, pp. 1572–1579, 2011.

[35] J. Y. Oh, R. H. Lee, J. M. Yu et al., “Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response,” Molecular Therapy, vol. 20, no. 11, pp. 2143–2152, 2012.

[36] K. C. Rustad and G. C. Gurtner, “Mesenchymal stem cells home to sites of injury and inflammation,” Advances in Wound Care, vol. 1, no. 4, pp. 147–152, 2012.

[37] A. Trounson and C. McDonald, “Stem cell therapies in clinical trials: progress and challenges,” Cell Stem Cell, vol. 17, no. 1, pp. 11–22, 2015.

[38] E. Beyaziyidiz, F. A. Pinarli, Ö. Beyaziyidiz et al., “Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model,” Stem Cells International, vol. 2014, Article ID 250230, 9 pages, 2014.

[39] S. Z. Josefowicz, L.-F. Lu, and A. Y. Rudensky, “Regulatory T cells: mechanisms of differentiation and function,” Annual Review of Immunology, vol. 30, pp. 531–564, 2012.

[40] S. M. Lieberman, P. A. Kreiger, and G. A. Koretzky, “Reversible lacrimal gland-protective regulatory T-cell dysfunction underlies male-specific autoimmune dacryoadenitis in the non-obese diabetic mouse model of Sjögren syndrome,” Immunology, vol. 145, no. 2, pp. 232–241, 2015.

[41] S. Sakaguchi, “The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery?” Journal of Clinical Investigation, vol. 112, no. 9, pp. 1310–1312, 2003.

[42] M. K. Leving, R. Bacchetta, U. Schulz, and M. G. Roncarolo, “The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells,” International Archives of Allergy and Immunology, vol. 129, no. 4, pp. 263–276, 2002.

[43] N. G. Singer and A. I. Caplan, “Mesenchymal stem cells: mechanisms of inflammation,” Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 457–478, 2011.

[44] M. Z. Ratajczak, E. Zuba-Surma, M. Kucia, R. Reca, W. Wojakowski, and J. Ratajczak, “The pleiotropic effects of the p53 tumor suppressor gene/protein 6,” Stem Cells, vol. 29, no. 10, pp. 1572–1579, 2011.

[45] F. Carubbi, P. Cipriani, A. Marrelli et al., “Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study,” Arthritis Research and Therapy, vol. 15, no. 5, article no. R172, 2013.

[46] L. Chiang, S. Karvar, and S. F. Hamm-Alvarez, “Direct imaging of Rab27a-enriched secretory vesicle biogenesis in lacrimal
acinar cells reveals origins on a nascent vesicle budding site," *PLoS ONE*, vol. 7, no. 2, Article ID e31789, 2012.

[47] L. Chiang, J. Ngo, J. E. Schechter et al., “Rab27b regulates exocytosis of secretory vesicles in acinar epithelial cells from the lacrimal gland,” *AJP: Cell Physiology*, vol. 301, no. 2, pp. C507–C521, 2011.

[48] E. Evans, W. Zhang, G. Jerdeva et al., “Direct interaction between Rab3D and the polymeric immunoglobulin receptor and trafficking through regulated secretory vesicles in lacrimal gland acinar cells,” *American Journal of Physiology - Cell Physiology*, vol. 294, no. 3, pp. C662–C674, 2008.

[49] T. Matsuzaki, T. Suzuki, H. Koyama, S. Tanaka, and K. Takata, “Aquaporin-5 (AQP5), a water channel protein, in the rat salivary and lacrimal glands: immunolocalization and effect of secretory stimulation,” *Cell and Tissue Research*, vol. 295, no. 3, pp. 513–521, 1999.

[50] Z. Meng, M. C. Edman, P.-Y. Hsueh et al., “Imbalanced Rab3d versus Rab27 increases cathepsin S secretion from lacrimal acini in a mouse model of Sjögren’s syndrome,” *American Journal of Physiology—Cell Physiology*, vol. 310, no. 11, pp. C942–C954, 2016.

[51] K. Tsuda, S. Hirai, L. S. King, P. Agre, and N. Ishida, “Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren’s syndrome,” *Lancet*, vol. 357, no. 9257, pp. 688–689, 2001.

[52] S. Steinfeld, E. Cogan, L. S. King, P. Agre, R. Kiss, and C. Delporte, “Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren’s syndrome patients,” *Laboratory Investigation*, vol. 81, no. 2, pp. 143–148, 2001.